Form 4: Artivion Executive Sells Shares Under Pre-Arranged Trading Plan

Artivion, Inc. SVP Marshall S. Stanton sold 15,000 shares of common stock for $29.50 per share under a Rule 10b5-1 trading plan.

Summary

• Marshall S. Stanton, SVP, Clinical & MD Affair at Artivion, Inc. (AORT), reported the sale of company common stock.
• A total of 15,000 shares were sold on June 17, 2025.
• The shares were sold at a price of $29.50 per share.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which was adopted on March 14, 2025.
• Following these sales, Mr. Stanton beneficially owns 64,200 shares of Artivion common stock.

Sentiment

Score: 5

Explanation: Neutral. A Form 4 filing reporting an insider sale under a 10b5-1 plan is generally considered a routine disclosure and does not inherently indicate positive or negative sentiment about the company's prospects. The sale is pre-scheduled, not reactive.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to immediate market conditions, which often mitigates concerns about opportunistic selling.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the insider's direct ownership in the company, which some investors may view as a slight negative.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is a Form 4 filing focused solely on insider stock transactions.

Management Comments

• "The sale reported on this form was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on March 14, 2025."

Industry Context

This Form 4 filing is specific to an insider transaction at Artivion, Inc. and does not provide information directly related to broader industry trends or competitor activities. Insider sales under 10b5-1 plans are common across various industries as a means for executives to manage personal finances while complying with insider trading regulations.

Related Party Transactions

• Marshall S. Stanton, SVP, Clinical & MD Affair, sold 15,000 shares of Artivion, Inc. common stock for $29.50 per share. This is a transaction between an insider (related party) and the company's stock market.

Stakeholder Impact

• Shareholders: The sale by a senior executive, even under a pre-arranged plan, slightly reduces insider ownership, which some investors might monitor as a signal, though the 10b5-1 plan typically mitigates concerns about opportunistic selling.

Key Dates

Keywords

Artivion, AORT, SEC Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Marshall S. Stanton, Beneficial Ownership